How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Appraisals often bring a mix of excitement and nerves, but for one Bengaluru startup employee, the latest review brought joy not just to him, but to his entire family. Raj Vikramaditya, founder of ...

Hiring in the age of artificial intelligence is becoming increasingly difficult, with one Bengaluru founder saying a flood of low-effort, AI-generated applications is making it harder to spot genuine ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

A Bengaluru-based entrepreneur who spent three-and-a-half years at Google before resigning to build a startup claims he has turned down an offer to return to the tech giant. Raj Vikramaditya, the ...

Gain the skills, dexterity and confidence to propel your career into senior management. Whether the goal is to create a standalone solution or fashion part of a complex talent development initiative, ...

That post quickly picked up traction, with many opining about the usage of AI in resumes and job interviews.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

*In the video above, IMF's Roger Nord and Kentaro Ogata, Deputy Director-General of the International Bureau of the Ministry of Finance of Japan discuss the importance of Japan’s support for the ...